Coloplast A/S (CLPBY)
12.71
+0.17
(+1.39%)
USD |
OTCM |
May 22, 16:00
Coloplast Enterprise Value: 31.87B for May 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 22, 2024 | 31.87B |
| May 21, 2024 | 31.48B |
| May 20, 2024 | 31.38B |
| May 17, 2024 | 31.53B |
| May 16, 2024 | 31.08B |
| May 15, 2024 | 31.47B |
| May 14, 2024 | 30.68B |
| May 13, 2024 | 30.77B |
| May 10, 2024 | 30.90B |
| May 09, 2024 | 31.02B |
| May 08, 2024 | 30.74B |
| May 07, 2024 | 30.61B |
| May 06, 2024 | 31.62B |
| May 03, 2024 | 31.20B |
| May 02, 2024 | 30.39B |
| May 01, 2024 | 30.75B |
| April 30, 2024 | 30.70B |
| April 29, 2024 | 31.40B |
| April 26, 2024 | 31.30B |
| April 25, 2024 | 31.58B |
| April 24, 2024 | 33.27B |
| April 23, 2024 | 33.11B |
| April 22, 2024 | 32.41B |
| April 19, 2024 | 32.46B |
| April 18, 2024 | 32.23B |
| Date | Value |
|---|---|
| April 17, 2024 | 32.43B |
| April 16, 2024 | 32.68B |
| April 15, 2024 | 32.52B |
| April 12, 2024 | 32.46B |
| April 11, 2024 | 33.76B |
| April 10, 2024 | 33.17B |
| April 09, 2024 | 33.22B |
| April 08, 2024 | 33.31B |
| April 05, 2024 | 33.40B |
| April 04, 2024 | 33.22B |
| April 03, 2024 | 33.40B |
| April 02, 2024 | 33.24B |
| April 01, 2024 | 33.85B |
| March 31, 2024 | 33.72B |
| March 28, 2024 | 33.36B |
| March 27, 2024 | 33.41B |
| March 26, 2024 | 33.32B |
| March 25, 2024 | 33.39B |
| March 22, 2024 | 33.30B |
| March 21, 2024 | 33.36B |
| March 20, 2024 | 33.75B |
| March 19, 2024 | 33.23B |
| March 18, 2024 | 33.57B |
| March 15, 2024 | 33.86B |
| March 14, 2024 | 33.75B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
22.81B
Minimum
May 29 2019
40.57B
Maximum
Aug 05 2021
30.54B
Average
30.34B
Median
Enterprise Value Benchmarks
| Genmab A/S | 14.98B |
| Ascendis Pharma A/S | 7.867B |
| Galecto Inc | -10.43M |
| Evaxion Biotech AS | 22.93M |
| IO Biotech Inc | -30.36M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 182.36M |
| Revenue (Quarterly) | 959.30M |
| Total Expenses (Quarterly) | 698.43M |
| EPS Diluted (Quarterly) | 0.0811 |
| Gross Profit Margin (Quarterly) | 67.98% |
| Profit Margin (Quarterly) | 19.01% |
| Earnings Yield | 2.57% |
| Operating Earnings Yield | 3.65% |
| Normalized Earnings Yield | 2.557 |